SCHEMBL3772185

SCHEMBL3772185

COC(=O)C(C)Oc1ccc(F)c2[nH]c(=O)c(Cc3ccc(Cl)cc3Cl)c(C)c12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
GAA P10253 4/20 0.36
ALDH1A1 P00352 4/20 0.36
LMNA P02545 3/20 0.35
HTT P42858 2/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 2/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772179 1.00 KDM4E (0.40) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3773014 1.00 KDM4E (0.40) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3773003 0.84 KDM4E (0.40) KDM4EL3MBTL1SMN1; SMN2HPGDTDP1
SCHEMBL3777364 0.84 SMN1; SMN2 (0.39) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3777368 0.84 SMN1; SMN2 (0.39) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3777793 0.80 HPGD (0.39) KDM4ESMN1; SMN2HPGDMEN1KMT2A
SCHEMBL3785180 0.79 KDM4E (0.47) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3781883 0.78 ALDH1A1 (0.40) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3776116 0.78 MEN1 (0.39) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1
SCHEMBL3782942 0.78 MEN1 (0.39) KDM4EL3MBTL1SMN1; SMN2HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 KDM4E 4638/4885L3MBTL1 3442/4885SMN1; SMN2 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.